Board summary
Key figures
36,093
Registered population
56.5% aged 18–64
23.7%
Aged 65+
ICB 21.9% · England 17.9%
7.2%
Ethnic minority (non-White)
2.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 9.2% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,359
Hypertension register
+2.83% in 3 yrs · England +5.60%
363
SMI register
53.9% of Adur's
712
COPD register
Reviews -10.92% in 3 yrs
Forecast to 2030
6,761
Hypertension patients, 2030
+402 on today
67.6%
QRISK ≥20% on statins, 2030
+4.04pp over 3 yrs
6.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension control and lipid therapy lag England.
Despite 91.3% BP monitoring, hypertension control fell 4.5 pp to 66.3% (England 70.3%) and high-risk lipid therapy is 58.6% (England 63.6%).
Respiratory and SMI annual reviews trail benchmarks.
Asthma reviews reach 57.5% (1,092 unreviewed; England 65.7%), COPD reviews 68.8% (England 76.4%) and SMI BMI checks 74.6% (England 82.1%).
Screening and age-five MMR1 uptake exceed England.
Breast screening is 83.0% (England 69.9%), cervical screening aged 25-49 is 73.5% (England 66.8%) and age-5 MMR1 reaches 98.9% (England 91.7%).
Population, age and ethnicity
With 23.7% aged 65+, an older demographic may shape chronic care needs
Shoreham and Southwick PCN serves 36,093 registered patients across a single practice, Adur Health Partnership. Patients aged 65+ comprise 23.7% (8,542) of the list, exceeding Adur (23.3%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Those aged 18–64 represent 56.5% (20,398; Adur 58.0%, ICB 60.5%, England 62.7%), and aged 0–17 represent 19.8% (7,153; Adur 18.7%, ICB 17.7%, England 19.6%). Census resident data (not registered patients) shows 92.8% White (Adur 93.4%, ICB 91.0%, England 81.1%), with 7.2% non-White. Projected 2030 list growth is 0.5% (method unverified; Adur 0.7%, ICB 2.1%, England 2.3%).
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Adur local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Adur LA) | 2,174 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Adur LA) | 1,147 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Adur LA) | 14.3 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.0 with 0.0% in Core20 despite substantial clinical caseloads
The PCN records an average IMD decile of 7.0, above Adur (6.6), NHS Sussex Integrated Care Board (6.1) and England (5.5), with 0.0% of registered patients in Core20 (England 21.0%), zero estimated Core20 residents and zero associated LSOAs in deciles 1 or 2. However, the PCN manages 363 severe mental illness patients (53.9% of Adur's register), where physical health checks lag England: BMI recording is 74.6% (England 82.1%) and alcohol recording is 71.0% (England 81.8%). With zero Core20 areas, tackling health inequalities relies on targeting clinical registers rather than geographic.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
363
SMI register
1.00% recorded prevalence
141
Learning disability register
0.39% recorded prevalence
11
Care homes, 357 beds
In the PCN catchment
9.4%
Provide unpaid care
Adur, Census 2021
The PCN records 363 severe mental illness patients (1.0%; Adur 1.0%, ICB 1.1%, England 1.0%) and 141 learning disability patients (0.4%; Adur 0.5%, ICB 0.6%, England 0.6%). Catchment facilities include 11 care homes with 357 beds, alongside borough-level Adur context of 9.4% unpaid carers. Recorded learning disability prevalence sits below comparators, though crude prevalence does not establish unmet need or under-detection.
Severe mental illness: physical health checks
For patients on the severe mental illness register, BMI recording fell 5.4 pp over 2023 to 2025 to 74.6% (England 82.1%, +5.1 pp), while blood pressure check coverage is 77.6% (England 83.4%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,359
Hypertension register
+2.83%
Register growth, 3 yrs
Adur +5.74% · England +5.60%
−0.89pp
BP control, under 80
≤140/90 · +1.44pp aged 80+
+402
More patients by 2030
Forecast 6,761 (18.54%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.5% (6,359 patients), above England (15.2%) and NHS Sussex ICB (16.3%), though below Adur (19.2%). Monitoring reach is strong, with 91.3% receiving a recent blood pressure check (England 90.0%). However, patients treated to target fell 4.5 pp (-6.3%) over 2023 to 2025 to 66.3%, trailing Adur (68.1%), the ICB (69.1%) and England (70.3%, +2.5 pp). Crude register figures are not age-adjusted. With blood pressure control falling below national benchmarks despite high testing rates, clinical review and medication titration appear to be key operational priorities.
Lipids and statins
Among patients with QRISK ≥ 20%, 58.6% receive lipid-lowering therapy, trailing Adur (61.1%), NHS Sussex ICB (60.0%) and England (63.6%). CKD lipid coverage is also lower at 66.1% (England 70.3%). Fewer at-risk cardiovascular patients receive lipid-lowering therapy than national rates imply, highlighting an immediate opportunity for systematic primary prevention recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 54,870 | £2.70 | £2.42 | £1.86 | £148,149 |
| Cardiovascular (all), 2025 | 77,941 | £3.60 | £3.32 | £3.33 | £280,588 |
In 2026, the PCN prescribed 54,870 items for lipid-regulating drugs at £2.70 per item (Adur £3.54, NHS Sussex ICB £2.42, England £1.86), spending £46,091 more than at England's unit cost across 54,870 items. Review of formulary choices could help align unit costs without compromising treatment coverage.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.88%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.28%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.5% (2,570 patients; England 6.6%), but 12-month reviews fell 3.9% over 2023 to 2025 to 57.5% (England 65.7%, +4.4%), leaving about 1,100 unreviewed patients. COPD reviews fell 10.9% over 2023 to 2025 to 68.8% (England 76.4%, +2.8%) with 2.0% prevalence (712 patients). Recorded second-hand smoking status for ages 6–19 reached 88.4% (England 78.8%), while asthma prescribing for ages 5–19 was 1,195 per 1,000 (England 1,488). Falling review coverage across asthma and COPD could reflect recall capacity constraints, unverified locally.
Cancer register and children's immunisation
Cancer prevalence is 5.4% (1,969 patients; England 3.8%). In Q1 2025/26 childhood immunisations, 12-month 6-in-1 coverage is 97.0% and age-5 MMR dose 1 is 98.9%, both exceeding the 95.0% target. However, 24-month coverage sits below the 95.0% target by 8.4 pp for 6-in-1 (86.6%) and by 5.4 pp for MMR dose 1 (89.6%), while age-5 MMR dose 2 is 94.6% (4.3 pp below dose 1).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
PCN cancer prevalence is 5.4% (1,969 patients, +10.5% over 2023 to 2025; England +9.0%). Screening coverage exceeds England for breast (83.0% vs 69.9%) and cervical ages 25–49 (73.5% vs 66.8%), though cervical coverage fell 1.0% over 2023 to 2025 (England -1.0%). Across NHS Sussex ICB, 58.5% of cancers with a known stage were diagnosed at stage 1 or 2 in 2022 (4,799 of 8,209; England 55.3%), 16.5 pp below the 75.0% national ambition by 2028 (about 1,360 extra early-stage cases needed). Known stage was recorded for 64.3% of registrations (England 67.0%). Staging is published at ICB level only.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day referral to treatment standard, below the 85.0% standard by 19.8 pp (NHS Surrey and Sussex ICB 71.5%, England 71.2%, Surrey and Sussex Healthcare NHS Trust 70.0%, East Sussex Healthcare NHS Trust 67.0%). The trust reached 74.0% on the 28-day faster diagnosis standard (standard 75.0%; England 79.3%) and 76.8% for 31-day treatment (standard 96.0%; England 92.5%). Diagnostic tests waiting 6+ weeks reached 12.9% overall (England 23.1%), with 39.3% for colonoscopy and 45.4% for flexi sigmoidoscopy (England 30.8% and 32.1%).
| Pathways within standard (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 84.20 | 77.74 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 98.19 | 96.20 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 67.04 | 69.97 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | East Sussex Healthcare | Surrey and Sussex Healthcare | England |
|---|---|---|---|---|
| MRI | 5.62 | 6.48 | 27.53 | 21.40 |
| CT | 8.57 | 0.48 | 18.49 | 9.92 |
| Echocardiography | 0.39 | 21.94 | 43.78 | 28.48 |
| Colonoscopy | 39.35 | 0.74 | 15.11 | 30.83 |
| Gastroscopy | 20.02 | 0.31 | 21.06 | 29.02 |
| All 15 DM01 tests | 12.95 | 5.27 | 28.50 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026 (provisional), West Sussex recorded 115,485 community care activities and 78,050 care contacts across 19,770 patients, alongside 16,015 referrals. Adults aged 65+ accounted for 72.7% of all contacts (56,740 of 78,050). Across NHS Surrey and Sussex ICB, 309,615 contacts were recorded for 85,660 patients. These experimental figures reflect submitting providers across local authority and ICB geographies rather than an exclusive PCN cohort.
Practice variation and patient experience
Overall QOF reaches 98.1% while website contact ease trails England at 33.6%
In 2025/26, Adur Health Partnership achieved 98.1% overall QOF points (England 92.5%) and 100.0% in the clinical domain (England 97.1%). Vaccination achievement reached 83.3% (England 55.2%). The personalised care adjustment rate across all domains was 10.0%, matching England (10.0%). Domain points measure recorded indicator achievement and are distinct from overall population reach.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Adur Health | 189 | 0.0 | 49.3% | 71.3% | 78.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across 25 measures, 15 trail England's three-year change, led by chronic disease annual reviews
Across 25 compared measures, 15 trail England's three-year change. The widest relative declines are in annual reviews: heart failure fell 13.8% (England +8.7%) and COPD fell 10.9% (England +2.8%). Mental health checks also lagged, with alcohol recording down 5.5 pp (England +5.4 pp) and BMI recording down 5.4 pp (England +5.1 pp). Conversely, three-year relative gains exceeded England for diabetic statins without cardiovascular disease (+7.6% vs +2.1%) and breast screening (+9.6% vs +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Alcohol record (psychosis)
BMI record (SMI)
Hypertension treated to target
Diabetes statin (no CVD)
Diabetes statin (CVD)
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Adur | Asset | PCN | Adur |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (357 beds) | n/a | Schools (catchment) | 23 | n/a |
| Children's centres | 2 | 4 | Places of worship | 19 | 29 |
| Libraries | 2 | 3 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 4 | 5 | Primary academies | 5 | 7 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension and lipid escalation review
Hypertension treated to target is 66.3% across 6,359 patients (Adur 68.1%, ICB 69.1%, England 70.3%), falling 4.5 pp over 2023 to 2025 (England +2.5 pp), while QRISK ≥ 20% lipid therapy is 58.6% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Respiratory annual review recall redesign
Asthma 12-month review coverage is 57.5% across 2,570 patients (Adur 60.1%, ICB 62.5%, England 65.7%), falling 3.9% (England +4.4%) and leaving 1,092 unreviewed; COPD reviews fell 10.9% to 68.8% (712 patients, England 76.4%). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
SMI checks and LD validation
Across 363 SMI patients (53.9% of Adur's register), BMI checks fell 5.4 pp to 74.6% (England 82.1%, +5.1 pp) and alcohol fell 5.5 pp to 71.0% (England 81.8%); LD prevalence is 0.4% (141 patients, gap +56 to +71). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult proactive care (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Inclusion health register outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration review (p5) | Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood booster recall audit (p6) | 6-in-1 complete primary course at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening audit and recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Digital and telephony access overhaul (p9) | GPPS easy to contact the practice using its website | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension and lipid escalation review (p12) | Hypertension register · Hypertension patients treated to target · Hypertension patients treated to appropriate threshold | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Respiratory annual review recall redesign (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 3 · SMI checks and LD validation (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope · 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
